Nanoscope's Light-Sensing Eye Gene Therapy: Randomized Macular Degeneration Data Are Promised, Not Yet Seen

Losing sight is one of the most feared parts of growing older. A Texas company has presented a gene therapy that tries to make surviving retinal cells sense light, and it has human data in one rare disease. Whether it works in the far more common macular degeneration is the open question.

Nanoscope Therapeutics announced on September 23, 2026 that it would present macular degeneration and retinitis pigmentosa data in Vienna. Retina specialist Jordi Monés, of the Institut de la Màcula in Barcelona and a member of Nanoscope's advisory committee, was scheduled to present at the 26th Euretina Congress on October 4 a paper titled 'Vision Improvement in Macular Degeneration with Sonpiretigene Isteparvovec Optogenetic Therapy: First Direct-to-Phase 2 Randomized, Controlled Trial'.

The Retina Forum on September 30 carried a company talk and a geographic atrophy panel, not the randomized data. On October 1, Nanoscope also presented a 4-year REMAIN/RESTORE ePoster in retinitis pigmentosa. That was long-term follow-up, not new randomized data.

The presentation dates and presenter are confirmed by the company's September 23 release. These are company statements. 'First' applies only to macular degeneration: the earlier RESTORE trial in retinitis pigmentosa was also randomized and shamcontrolled.

The drug itself is real and well documented. Sonpiretigene isteparvovec is the formal name for MCO-010. It uses an adeno-associated virus to deliver a gene for a multicharacteristic opsin, a light-sensitive protein, into bipolar cells of the retina. Those cells normally sit one step behind the rods and cones. When rods and cones die, the plan is to make the next layer do the sensing.

A 2024 paper in Translational Vision Science & Technology by Nanoscope scientists reported that a single injection into the eye reached about 80% of bipolar cells in two mouse models of retinitis pigmentosa. Treated mice navigated a water maze faster, kept more retinal thickness, and showed no ocular toxicity, including under intense light.

A 2026 company paper in Bioengineering reported improved visual behavior and electrical responses in a mouse model of Stargardt disease, a form of inherited macular degeneration. It found no change in retinal thickness.

There are also human data. The RESTORE Phase 2b/3 trial in retinitis pigmentosa was randomized and sham-controlled (27 participants) and met its best-corrected visual acuity endpoints at 52 weeks. An open-label Stargardt study reported gains of about 12 ETDRS letters. In 2025 the Institute for Clinical and Economic Review, an independent US group that judges value for money, published an assessment of sonpiretigene for advanced retinitis pigmentosa in the Journal of Managed Care & Specialty Pharmacy. The FDA has since accepted Nanoscope's biologics license application for the drug (proposed brand name MOGENRY) in retinitis pigmentosa, with a decision date in the first half of 2027.

Geographic atrophy is the advanced dry form of age-related macular degeneration. It is a leading cause of severe vision loss in older adults, and current treatments only slow it. A therapy that works regardless of which gene or process killed the photoreceptors could, in principle, help many conditions at once.

That is the promise of optogenetics. It does not repair the original damage. It gives surviving cells a new job.

• No numbers yet. The announcement gave only a title and a time, with no sample size, endpoints or results, and we found no public report of the October 4 talk. • The weakest point is geographic atrophy. We found no peer-reviewed work there. Coverage of the 2026 American Academy of Ophthalmology meeting said no registry record for the trial could be found, so its size and status are unclear. • Human evidence is in retinitis pigmentosa, in a small trial of 27 people. Stargardt gains come from an open-label study without a control group. • Company-run data. Results presented at meetings are not peer reviewed. Wait for the full paper.

• If you are over 55, get a dilated eye exam on the schedule your eye doctor advises. Early macular degeneration has few symptoms. • Do not smoke. Smoking is a well-established risk factor for macular degeneration. • If you have retinitis pigmentosa or geographic atrophy, ask a retina specialist about trial eligibility rather than seeking therapies abroad.

• The full randomized macular degeneration dataset, with sample size and endpoints, in a peer-reviewed journal. • Whether the benefit seen in retinitis pigmentosa holds in geographic atrophy. • Independent, non-company replication of the vision-restoring effect.

Moderna's 2026 Rally Tops 500%, Driven Mostly by One Melanoma Vaccine Trial